Epaminondas Markos Valsamis MRCS , Marie Louise Jensen MD , Gillian Coward , Adrian Sayers PhD , Rafael Pinedo-Villanueva PhD , Jeppe V Rasmussen PhD , Prof Gary S Collins PhD , Prof Jonathan L Rees FRCS
{"title":"初次肩关节置换术后发生严重不良事件的风险:利用英格兰和丹麦的关联国家数据开发预测模型并进行外部验证。","authors":"Epaminondas Markos Valsamis MRCS , Marie Louise Jensen MD , Gillian Coward , Adrian Sayers PhD , Rafael Pinedo-Villanueva PhD , Jeppe V Rasmussen PhD , Prof Gary S Collins PhD , Prof Jonathan L Rees FRCS","doi":"10.1016/S2665-9913(24)00149-8","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Despite a rising rate of serious medical complications after shoulder replacement surgery, there are no prediction models in widespread use to guide surgeons in identifying patients at high risk and to provide patients with personalised risk estimates to support shared decision making. Our aim was to develop and externally validate a prediction model for serious adverse events within 90 days of primary shoulder replacement surgery.</p></div><div><h3>Methods</h3><p>Linked data from the National Joint Registry, National Health Service Hospital Episode Statistics Admitted Patient Care of England, and Civil Registration Mortality databases and Danish Shoulder Arthroplasty Registry and National Patient Register were used for our modelling study. Patients aged 18–100 years who had a primary shoulder replacement between April 1, 2012, and Oct 2, 2020, in England, and April 1, 2012, and Oct 2, 2018, in Denmark, were included. We developed a multivariable logistic regression model using the English dataset to predict the risk of 90-day serious adverse events, which were defined as medical complications requiring admission to hospital and all-cause death. We undertook internal validation using bootstrapping, and internal–external cross-validation across different geographical regions of England. The English model was externally validated on the Danish dataset.</p></div><div><h3>Findings</h3><p>Data for 40 631 patients undergoing primary shoulder replacement (mean age 72·5 years [SD 9·9]; 28 709 [70·7%] women and 11 922 [29·3%] men) were used for model development, of whom 2270 (5·6%) had a 90-day serious adverse event. On internal validation, the model had a C-statistic of 0·717 (95% CI 0·707–0·728) and was well calibrated. Internal–external cross-validation showed consistent model performance across all regions in England. Upon external validation on the Danish dataset (n=6653; mean age 70·5 years [SD 10·3]; 4503 [67·7%] women and 2150 [32·3%] men), the model had a C-statistic of 0·750 (95% CI 0·723–0·776). Decision curve analysis showed clinical utility, with net benefit across all risk thresholds.</p></div><div><h3>Interpretation</h3><p>This externally validated prediction model uses commonly available clinical variables to accurately predict the risk of serious medical complications after primary shoulder replacement surgery. The model is generalisable and applicable to most patients in need of a shoulder replacement. Its use offers support to clinicians and could inform and empower patients in the shared decision-making process.</p></div><div><h3>Funding</h3><p>National Institute for Health and Care Research and the Department of Orthopaedic Surgery, Herlev and Gentofte Hospital, Denmark.</p></div>","PeriodicalId":48540,"journal":{"name":"Lancet Rheumatology","volume":"6 9","pages":"Pages e607-e614"},"PeriodicalIF":15.0000,"publicationDate":"2024-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2665991324001498/pdfft?md5=a55adae7a4a237278e80aab4c7d56111&pid=1-s2.0-S2665991324001498-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Risk of serious adverse events after primary shoulder replacement: development and external validation of a prediction model using linked national data from England and Denmark\",\"authors\":\"Epaminondas Markos Valsamis MRCS , Marie Louise Jensen MD , Gillian Coward , Adrian Sayers PhD , Rafael Pinedo-Villanueva PhD , Jeppe V Rasmussen PhD , Prof Gary S Collins PhD , Prof Jonathan L Rees FRCS\",\"doi\":\"10.1016/S2665-9913(24)00149-8\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>Despite a rising rate of serious medical complications after shoulder replacement surgery, there are no prediction models in widespread use to guide surgeons in identifying patients at high risk and to provide patients with personalised risk estimates to support shared decision making. Our aim was to develop and externally validate a prediction model for serious adverse events within 90 days of primary shoulder replacement surgery.</p></div><div><h3>Methods</h3><p>Linked data from the National Joint Registry, National Health Service Hospital Episode Statistics Admitted Patient Care of England, and Civil Registration Mortality databases and Danish Shoulder Arthroplasty Registry and National Patient Register were used for our modelling study. Patients aged 18–100 years who had a primary shoulder replacement between April 1, 2012, and Oct 2, 2020, in England, and April 1, 2012, and Oct 2, 2018, in Denmark, were included. We developed a multivariable logistic regression model using the English dataset to predict the risk of 90-day serious adverse events, which were defined as medical complications requiring admission to hospital and all-cause death. We undertook internal validation using bootstrapping, and internal–external cross-validation across different geographical regions of England. The English model was externally validated on the Danish dataset.</p></div><div><h3>Findings</h3><p>Data for 40 631 patients undergoing primary shoulder replacement (mean age 72·5 years [SD 9·9]; 28 709 [70·7%] women and 11 922 [29·3%] men) were used for model development, of whom 2270 (5·6%) had a 90-day serious adverse event. On internal validation, the model had a C-statistic of 0·717 (95% CI 0·707–0·728) and was well calibrated. Internal–external cross-validation showed consistent model performance across all regions in England. Upon external validation on the Danish dataset (n=6653; mean age 70·5 years [SD 10·3]; 4503 [67·7%] women and 2150 [32·3%] men), the model had a C-statistic of 0·750 (95% CI 0·723–0·776). Decision curve analysis showed clinical utility, with net benefit across all risk thresholds.</p></div><div><h3>Interpretation</h3><p>This externally validated prediction model uses commonly available clinical variables to accurately predict the risk of serious medical complications after primary shoulder replacement surgery. The model is generalisable and applicable to most patients in need of a shoulder replacement. Its use offers support to clinicians and could inform and empower patients in the shared decision-making process.</p></div><div><h3>Funding</h3><p>National Institute for Health and Care Research and the Department of Orthopaedic Surgery, Herlev and Gentofte Hospital, Denmark.</p></div>\",\"PeriodicalId\":48540,\"journal\":{\"name\":\"Lancet Rheumatology\",\"volume\":\"6 9\",\"pages\":\"Pages e607-e614\"},\"PeriodicalIF\":15.0000,\"publicationDate\":\"2024-07-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2665991324001498/pdfft?md5=a55adae7a4a237278e80aab4c7d56111&pid=1-s2.0-S2665991324001498-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Lancet Rheumatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2665991324001498\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"RHEUMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lancet Rheumatology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2665991324001498","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景:尽管肩关节置换手术后严重医疗并发症的发生率不断上升,但目前还没有广泛使用的预测模型来指导外科医生识别高风险患者,并为患者提供个性化的风险估计,以支持共同决策。我们的目标是开发并从外部验证一个肩关节置换手术后 90 天内严重不良事件的预测模型:我们的建模研究使用了来自国家关节登记处、英格兰国家卫生服务医院事件统计入院患者护理和民事登记死亡率数据库以及丹麦肩关节置换术登记处和国家患者登记处的关联数据。我们纳入了年龄在 18-100 岁之间、在英格兰于 2012 年 4 月 1 日至 2020 年 10 月 2 日期间、在丹麦于 2012 年 4 月 1 日至 2018 年 10 月 2 日期间接受过初次肩关节置换术的患者。我们利用英国的数据集建立了一个多变量逻辑回归模型,以预测90天严重不良事件的风险,这些不良事件被定义为需要入院治疗的医疗并发症和全因死亡。我们使用引导法进行了内部验证,并在英格兰不同地理区域进行了内部-外部交叉验证。英国模型在丹麦数据集上进行了外部验证:40 631 名接受初次肩关节置换术的患者(平均年龄 72-5 岁 [SD 9-9];女性 28 709 人 [70-7%] ,男性 11 922 人 [29-3%] )的数据被用于模型开发,其中 2270 人(5-6%)发生了 90 天严重不良事件。经内部验证,该模型的 C 统计量为 0-717(95% CI 0-707-0-728),校准良好。内部-外部交叉验证显示,模型在英格兰所有地区的表现一致。在丹麦数据集(n=6653;平均年龄 70-5 岁 [SD 10-3];4503 [67-7%] 女性和 2150 [32-3%] 男性)上进行外部验证后,该模型的 C 统计量为 0-750(95% CI 0-723-0-776)。决策曲线分析表明,该模型具有临床实用性,在所有风险阈值下均可获得净收益:这个经过外部验证的预测模型利用常见的临床变量来准确预测初级肩关节置换手术后出现严重医疗并发症的风险。该模型具有通用性,适用于大多数需要接受肩关节置换手术的患者。该模型的使用可为临床医生提供支持,并可在共同决策过程中为患者提供信息和授权:资金来源:丹麦国家健康与护理研究所(National Institute for Health and Care Research)和赫尔勒夫与根托夫特医院(Herlev and Gentofte Hospital)骨科手术部(Department of Orthopaedic Surgery)。
Risk of serious adverse events after primary shoulder replacement: development and external validation of a prediction model using linked national data from England and Denmark
Background
Despite a rising rate of serious medical complications after shoulder replacement surgery, there are no prediction models in widespread use to guide surgeons in identifying patients at high risk and to provide patients with personalised risk estimates to support shared decision making. Our aim was to develop and externally validate a prediction model for serious adverse events within 90 days of primary shoulder replacement surgery.
Methods
Linked data from the National Joint Registry, National Health Service Hospital Episode Statistics Admitted Patient Care of England, and Civil Registration Mortality databases and Danish Shoulder Arthroplasty Registry and National Patient Register were used for our modelling study. Patients aged 18–100 years who had a primary shoulder replacement between April 1, 2012, and Oct 2, 2020, in England, and April 1, 2012, and Oct 2, 2018, in Denmark, were included. We developed a multivariable logistic regression model using the English dataset to predict the risk of 90-day serious adverse events, which were defined as medical complications requiring admission to hospital and all-cause death. We undertook internal validation using bootstrapping, and internal–external cross-validation across different geographical regions of England. The English model was externally validated on the Danish dataset.
Findings
Data for 40 631 patients undergoing primary shoulder replacement (mean age 72·5 years [SD 9·9]; 28 709 [70·7%] women and 11 922 [29·3%] men) were used for model development, of whom 2270 (5·6%) had a 90-day serious adverse event. On internal validation, the model had a C-statistic of 0·717 (95% CI 0·707–0·728) and was well calibrated. Internal–external cross-validation showed consistent model performance across all regions in England. Upon external validation on the Danish dataset (n=6653; mean age 70·5 years [SD 10·3]; 4503 [67·7%] women and 2150 [32·3%] men), the model had a C-statistic of 0·750 (95% CI 0·723–0·776). Decision curve analysis showed clinical utility, with net benefit across all risk thresholds.
Interpretation
This externally validated prediction model uses commonly available clinical variables to accurately predict the risk of serious medical complications after primary shoulder replacement surgery. The model is generalisable and applicable to most patients in need of a shoulder replacement. Its use offers support to clinicians and could inform and empower patients in the shared decision-making process.
Funding
National Institute for Health and Care Research and the Department of Orthopaedic Surgery, Herlev and Gentofte Hospital, Denmark.
期刊介绍:
The Lancet Rheumatology, an independent journal, is dedicated to publishing content relevant to rheumatology specialists worldwide. It focuses on studies that advance clinical practice, challenge existing norms, and advocate for changes in health policy. The journal covers clinical research, particularly clinical trials, expert reviews, and thought-provoking commentary on the diagnosis, classification, management, and prevention of rheumatic diseases, including arthritis, musculoskeletal disorders, connective tissue diseases, and immune system disorders. Additionally, it publishes high-quality translational studies supported by robust clinical data, prioritizing those that identify potential new therapeutic targets, advance precision medicine efforts, or directly contribute to future clinical trials.
With its strong clinical orientation, The Lancet Rheumatology serves as an independent voice for the rheumatology community, advocating strongly for the enhancement of patients' lives affected by rheumatic diseases worldwide.